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No serious adverse effects were noted in either group. Phases of regular
tachycardia were observed in 3 pts of each group, but only in 2 cases, both
receiving placebo, 1: 1 AV conduction ensued.
1) Oral loading dose of PFN is safely and promptly efficacious in convert-
ing recent onset AF to SR. 2) The efficacy of oral PFN is significantly superior
in comparison to oral DIG while oral loading dose of DIG is no better than
placebo. 31 PFN and DIG are both effective in reducing MVR in pts with recent
onset AF who did not revert to SR or who reverted late after drug adminis-
tration.
Mean conversion time within 4 hours was 139 ± 117' for PFN, 123 ± 66' for
DIG and 116 ± 78' for PLA (p = ns).
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To date, it is unclear whether handy phones (C-net or D-net) can be used
safely by patients with permanent pacemakers. Possible interactions be-
tween handy phones and pacemaker function include: 1) inhibition of the
pacemaker, 21 change of temporary or permanent pacemaker programming,
and 3) switch to VOO mode.
Methods: Thirty pts (14 f, age: 48-87 years) with single chamber (13 pts)
or dual chamber pacemakers (17 pts) were studied during routine follow-
up in our outpatient department. Pacemaker sensing was unipolar in 17 pts,
and bipolar in 13 pts. After completion of the routine pacemaker check, each
pt was asked to make several phone calls with a handy phone IEricssonR;
D-net; 2.5 watts). A surface ECG (Mingograph) was recorded continuously
during each phone call in order to detect possible interactions between pace-
maker function and handy phone use. Phone calls were repeated after pace-
maker programming to 1) minimum ventricular rate of 90 bpm and previous
sensitivity, and 2) minimum rate of 90 bpm and maximum sensitivity without
T-wave oversensi ng.
Results: A change of the pacemaker programming or a switch to VOO pac-
ing due to handy phone calls was not observed in any pt. Two of 30 pts (3%)
reproducibly showed intermittent pacemaker inhibition during handy phone
calls. Both pacemakers had unipolar sensing. Both pts remained asymp-
tomatic during pacemaker inhibition since they were not completely pace-
A population of 105 patients (pts) with recent onset «72 hours) atrial fibril-
lation (AF) without clinical signs of heart failure were randomly treated with
a single loading oral dose of propafenone (PFN) (600 mg) or digoxin (DIG) (1
mg) or with placebo (PLA). A 24-hour holter monitoring was performed and
conversion to sinus rhythm (SR) after 2, 4 and 24 hours was considered as
criterion of efficacy. We also evaluated the effect on mean ventricular rate
IMVR) in those pts with still lasting AF four hours after drug administration.
The 3 groups were comparable as to gender, age, etiology, duration of AF,
mean ventricular rate at baseline and left atrial dimension.
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Conclusion: In pts with AF, precordial OTD increases significantly during
0- but not during S-therapy desp te a comparable increase in OTmax. Tliiis
finding may reflect a greater propensity for the development of proarrhyth-
mia associated with 0 therapy. Determination of OTD may help to increase
the safety of pharmacological therapy in this patient population.
OT dispersion (OTD;OTmax - OTmin) is considered to reflect inhomoge-
neous ventricular recovery. In pts with atrial fibrillation (AF), however, the ef-
fects of antiarrhythmic drugs on OTD have not been systematically evaluated
particularly with respect to their association with drug-induced proarrhyth-
mia. Thus, OTD was assessed in a prospective, randomized trial including 50
pts with AF receiving quinidine (0; 1000 mg/day) or sotalol (S;320 mg/day) in
an attempt to restore sinus rhythm (SRI. Precordial OTD was measured by
means of a digitizer-based software before and during drug therapy. Results:
22/25 O-treated pts converted to SR compared to 17/25 S pts (p = ns). There
were 4 cases of proarrhythmia (torsade de pointes in 3 pts, monomorphic
VT in 1 pt) in the 0- but none in the S-pts. Whereas ventricular depolariza-
tion (ORS) was not affected by either drug, 0 and S caused a comparable
increase in OTmax. OTD, however, increased only in the 0 group whereas no
significant changes were observed in S pts. OTD increased by >50% in all 3
pts with O-associated torsade de pointes.
AF from 353 ± 74 ms to 422 ± 81 ms (p < 0.01) after 30 min, and to 480 ±
99 ms (p < 0.01) after one week. MaxCL (504 ± 125 msl increased to 667 ±
173 ms (p < 0.01). and to 814 ± 467 ms (p < 0.01) respectively. SP ablation
reduced the duration of an AF episode (55 ± 93s) to 14 ± 13s (ns) and to 15
± 16s (ns). No significant difference was observed between the immediate
and follow-up results after one week although a tendency towards higher CL
was demonstrated.
Conclusion: Reduced ventricular response to atrial fibrillation after slow
pathway ablation of AVNRT is demonstrable immediately and during a follow-
up period of one week. Slow pathway ablation may have important implica-
tions for patients with atrial fibrillation refractory to medical treatment.
Quinidine or Sotalol-induced Changes in
QT-Dispersion During Pharmacological
Conversion Therapy of Atrial Fibrillation: Link to
Proarrhythmia as Assessed in a Prospective,
Randomized Trial
The clinical efficacy and safety of oral Sotalol in patients (pts) with refractory
atrial fibrillationlflutter (AF) has not been widely examined. We evaluated 31
pts with chronic (8 pts) or paroxysmal (23 pts) AF, 20 males, mean age 61 ± 8
yrs, LV ejection fraction was ::40 in 11 pts, coronary artery disease in 11 pts,
cardiomyopathy in 5 pts, valvular heart disease in 3 pts, no structural heart
disease in 12 pts. All pts had failed multiple 2.7 (range 1-4) antiarrhythmic
drug trials. Oral Sotalol therapy was commenced during AF in 15 pts and in
sinus rhythm in 16 pts and was titrated to maximally tolerated or effective
levels. All pts underwent 24 hr Holter monitor prior to discharge. Results:
Sotalol resulted in conversion to sinus rhythm in 12 of 15 (80%) pts. 2 pts
had recurrent AF. and 1 pt developed side effects while in the hospital. 28 pts
were discharged on a mean dose of 220 mg daily (range 80-320). During fol-
lowup of 8.2 mas (range 2-20) there were no sudden or cardiac deaths. None
of the pts demonstrated proarrhythmia on Holter monitor. 4 pts (12%) had
recurrence of AF. Sotalol was discontinued in 3 pts (S%) due to side effects.
22 of 31 pts (71 %1 were free of recurrent AF and side effects during fol-
lowup. Conclusions: (1) Sotalol is effective, safe and well tolerated for acute
conversion of AF to sinus rhythm as well as maintenance of sinus rhythm.
(2) Incidence of adverse effects including proarrhythmia is low in this pt pop-
ulation. (3) Effective dose of Sotalol for control of AF seems to be lower than
for ventricular tachycardia.
ORS (msec) aTmax Imsec) OTD (msec)
control drug control drug control drug
a 86 ± 17 gO ± 17 363 ± 38 411 ± 39# 34 ± 9 43 ± 14'
S 89 ± 21 89 ± 18 367 ± 40 425 ± 58# 36 ± 18 40 ± 17
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